Immunome (IMNM) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.50
- EPS estimate
- −$0.52
- EPS surprise
- +3.23%
- Revenue surprise
- +381.80%
- Revenue
- $4.0M
- Revenue estimate
- $833,333.00
- Reported
- Aug 6, 2025
Immunome reported Q2 2025 results on August 6, 2025. The company lost $0.50 per share, a smaller loss than the $0.52 estimate, a beat of 3.23%. Revenue was $4.0 million against an estimate of about $0.8 million, a revenue surprise of 381.80%. A year earlier, in Q2 2024, the loss was $0.60 per share and revenue was $2.4 million.
Every quarter in the table, from Q4 2020 to Q2 2025, was a loss. Full-year losses were $2.13 per share in 2021, $3.09 in 2022, $5.38 in 2023 and $5.00 in 2024. The deepest quarterly loss was Q4 2023, at $4.21 per share, followed by $2.51 in Q1 2024. Since then the losses have narrowed: the first half of 2025 lost $1.02 per share, against $3.11 in the first half of 2024. Revenue has stayed small, between $1.0 million and $4.3 million per quarter. Over the 19 quarters shown, Immunome beat the EPS estimate seven times and missed it 12 times.
The table shows no report after Q2 2025. In the period covered, third-quarter results came out in mid-November and fourth-quarter results in March. Newer figures will show whether the narrower losses of 2025 continued.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 6, 2025 | −$0.52 | −$0.50 | +3.23% | $4.0M | SEC |
| Q1 2025 | May 12, 2025 | −$0.63 | −$0.52 | +18.08% | $2.9M | SEC |
| Q4 2024 | Mar 19, 2025 | −$0.64 | −$1.11 | −73.22% | $2.7M | SEC |
| Q3 2024 | Nov 13, 2024 | −$0.55 | −$0.78 | −41.46% | $2.9M | SEC |
| Q2 2024 | Aug 12, 2024 | −$0.38 | −$0.60 | −58.14% | $2.4M | SEC |
| Q1 2024 | May 14, 2024 | −$0.68 | −$2.51 | −269.12% | $1.0M | SEC |
| Q4 2023 | Mar 28, 2024 | −$0.27 | −$4.21 | −1440.43% | $3.8M | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.17 | −$0.36 | −111.76% | $3.6M | SEC |
| Q2 2023 | Aug 9, 2023 | −$0.16 | −$0.46 | −187.50% | $4.3M | SEC |
| Q1 2023 | May 5, 2023 | $0.59 | −$0.35 | −159.83% | $2.4M | SEC |
| Q4 2022 | Mar 16, 2023 | −$0.68 | −$0.64 | +5.19% | $0.00 | SEC |
| Q3 2022 | Nov 14, 2022 | −$0.76 | −$0.75 | +1.32% | $0.00 | — |
| Q2 2022 | Aug 5, 2022 | −$0.93 | −$0.74 | +20.43% | $0.00 | — |
| Q1 2022 | May 12, 2022 | −$0.69 | −$0.96 | −39.13% | $0.00 | — |
| Q4 2021 | Mar 28, 2022 | −$0.81 | −$0.65 | +19.75% | $0.00 | — |
| Q3 2021 | Nov 15, 2021 | −$0.51 | −$0.65 | −28.71% | $0.00 | — |
| Q2 2021 | Aug 16, 2021 | −$0.39 | −$0.46 | −17.95% | $0.00 | — |
| Q1 2021 | May 12, 2021 | −$0.41 | −$0.37 | +9.76% | $0.00 | — |
| Q4 2020 | Mar 25, 2021 | −$0.29 | −$0.40 | −37.93% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Immunome (IMNM) last report earnings?
Immunome last reported on Aug 6, 2025, covering fiscal Q2 2025.
Did IMNM beat earnings estimates?
Yes. Immunome reported EPS of −$0.50 for Q2 2025 against a −$0.52 estimate — a 3.23% beat.
How much revenue did IMNM report last quarter?
Immunome reported $4.0M in revenue for Q2 2025, against a consensus estimate of $833,333.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.